Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
AUTONOMIX MEDICAL INC (AMIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.52-5.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AMIX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
secure funding through private placements | The company raised funds in private placements in 2025. | Under Pressure | failure to raise capital triggers delisting risk | Qualitative: Warrant exercise completed vs target of securing funding Warrant exercise and patent issued; reverse split and significant price decline signal ongoing financial distress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AMIX is a high-risk, loss-making growth and development story, not an established compounder. The thesis is still intact, but confidence is low and recent evidence of progress remains limited.
The evidence snapshot gives no valuation measure or direct account of market expectations, so it is not possible to say whether AMIX looks cheap, fair, or expensive versus peers. The main known expectation is that the company can make progress on clinical development and partnerships while controlling losses, but the evidence does not show those efforts producing clear financial results yet.
Over the multi-year view, losses may narrow if management continues improving operating performance, but the company remains loss-making and its cash-burn control is rated behind. Near term, erratic earnings and smaller-cap risk make the next results uncertain; management has also emphasized capital allocation, security-holder rights, and early-stage clinical and partnership work.
The thesis depends on whether loss control improves and clinical development or partnerships show measurable progress. In the near term, weakening job growth could increase recession concerns, while continued strong results from Healthcare bellwethers such as ABT, MDT, and SYK could support the sector backdrop; misses or weaker guidance could remove that support.
For the next 1 to 3 years, AMIX has an intact but low-confidence thesis: improving losses and progress in development are possible, while execution risk and uncertain sector conditions remain substantial. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in AUTONOMIX MEDICAL INC's published investment case. The stated target is EPS loss improves to >= -22.68 USD per share. |
| Intact |
| EPS loss does not improve beyond -34.12 USD per share by FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
maintain Nasdaq listing standards | A primary condition in AUTONOMIX MEDICAL INC's published investment case. The stated target is resolve Nasdaq deficiency and maintain listing. | Intact | Nasdaq delists the company or issues new deficiency notices | No delisting or new deficiency notice reported News shows reverse split and patent; no delisting or new deficiency notices reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-19.53 → $-3.95 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-19.53 | $900,000 | 1 / 1 |
| 2026-07-25 | $-19.53 | $900,000 | 1 / 1 |
| 2026-07-26 | $-19.53 | $900,000 | 1 / 1 |
| 2026-07-27 | $-19.53 | $900,000 | 1 / 1 |
| 2026-07-28 | $-19.53 | $900,000 | 1 / 1 |
| 2026-07-29 | $-19.53 | $0 | 2 / 2 |
| 2026-07-30 | $-19.53 | $0 | 2 / 2 |
| 2026-07-31 | $-19.53 | $0 | 2 / 2 |
| 2026-08-01 | $-19.53 | $0 | 2 / 2 |
| 2026-08-02 | $-19.53 | $0 | 2 / 2 |
| 2026-08-03 | $-19.53 | $0 | 2 / 2 |
| 2026-08-04 | $-19.53 | $0 | 2 / 2 |
| 2026-08-05 | $-19.53 | $0 | 2 / 2 |
| 2026-08-06 | $-19.53 | $0 | 2 / 2 |
| 2026-08-07 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-08 | $-19.53 | $0 | 2 / 2 |
| 2026-08-09 | $-19.53 | $0 | 2 / 2 |
| 2026-08-10 | $-19.53 | $0 | 2 / 2 |
| 2026-08-11 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-12 | $-19.53 | $0 | 2 / 2 |
| 2026-08-13 | $-19.53 | $0 | 2 / 2 |
| 2026-08-14 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-15 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-16 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-17 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-18 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-19 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-20 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-21 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-22 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-23 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-24 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-25 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-26 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-27 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-28 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-29 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-30 | $-19.53 | $900,000 | 1 / 1 |
| 2026-08-31 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-01 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-02 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-03 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-04 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-05 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-06 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-07 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-08 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-09 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-10 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-11 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-12 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-13 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-14 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-15 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-16 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-17 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-18 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-19 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-20 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-21 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-22 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-23 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-24 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-25 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-26 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-27 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-28 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-29 | $-19.53 | $900,000 | 1 / 1 |
| 2026-09-30 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-01 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-02 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-03 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-04 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-05 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-06 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-07 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-08 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-09 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-10 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-11 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-12 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-13 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-14 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-15 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-16 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-17 | $-19.53 | $900,000 | 1 / 1 |
| 2026-10-18 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-19 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-20 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-21 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-22 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-23 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-24 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-25 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-26 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-27 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-28 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-29 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-30 | $-3.95 | $900,000 | 1 / 1 |
| 2026-10-31 | $-3.95 | $900,000 | 1 / 1 |
| 2026-11-01 | $-3.95 | $900,000 | 1 / 1 |
| 2026-11-02 | $-3.95 | $900,000 | 1 / 1 |
| 2026-11-03 | $-3.95 | $900,000 | 1 / 1 |
| 2026-11-04 | $-3.95 | $900,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.